TrialInternational journal of clinical oncology2017

Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.

Ikuko Sugitani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.